US Patent Issued to Foundation Medicine on Feb. 24 for "KMT2A-MAML2 fusion molecules and uses thereof" (Massachusetts Inventor)

ALEXANDRIA, Va., Feb. 24 -- United States Patent no. 12,559,800, issued on Feb. 24, was assigned to Foundation Medicine Inc. (Boston).

"KMT2A-MAML2 fusion molecules and uses thereof" was invented by Erik Williams (Boston).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides KMT2A-MAML2 fusion nucleic acid molecules, and KMT2A-MAML2 fusion polypeptides, as well as methods, kits and reagents for detecting such KMT2A-MAML2 fusion nucleic acid molecules and KMT2A-MAML2 fusion polypeptides. The disclosure also provides methods for evaluating, identifying, assessing, and/or treating an individual having a cancer, such an epithelial neoplasm or a thymoma."

The patent was filed on Aug. 31, ...